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Background: Robot-assisted kidney transplantation (RAKT) has recently been introduced
to reduce the morbidity of open kidney transplantation (KT).
Objective: To evaluate perioperative and early postoperative RAKT outcomes.
Design, setting and participants: This was a multicenter prospective observational study
of 120 patients who underwent RAKT, predominantly with a living donor kidney, in eight
European institutions between July 2015 andMay 2017, with minimum follow-up of 1 mo.
The robot-assisted surgical steps were transperitoneal dissection of the external
iliac vessels, venous/arterial anastomosis, graft retroperitonealization, and ureterovesical
anastomosis.
Outcome measurements and statistical analysis: Descriptive analysis of surgical data and
their correlations with functional outcomes.
Results and limitations: The median operative and vascular suture time was 250 and
38min, respectively. The median estimated blood loss was 150ml. No major intraoperative
complications occurred, although two patients needed open conversion. The median
postoperative estimated glomerular filtration rate was 21.2, 45.0, 52.6, and 58.0 ml/min
on postoperative day 1, 3, 7, and 30, respectively. Both early and late graft functionwere not
related to overall operating time or rewarming time. Five cases of delayed graft function
(4.2%)were reported. One case (0.8%) ofwound infection, three cases (2.5%) of ileus, and four
cases of bleeding (3.3%; three ofwhich required blood transfusion), managed conservatively,
were observed. One case (0.8%) of deep venous thrombosis, one case (0.8%) of lymphocele,
and three cases (2.5%) of transplantectomy due to massive arterial thrombosis were
recorded. In five cases (4.2%), surgical exploration was performed for intraperitoneal
hematoma. Limitations of the study include selection bias, the lack of an open control
group, and failure to report on patient cosmetic satisfaction.
Conclusions: When performed by surgeons with robotic and KT experience, RAKT is safe
and reproducible in selected cases and yields excellent graft function.
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Table 1 – Robot-assisted kidney transplantations (RAKTs) carried
out at European centers
Institution RAKTs
(n)
Fundació Puigvert, Barcelona, Spain (pilot center) 20
Bakirkoy Sadi Konuk Training and Research Hospital Center Turkey 45
Hospital Clinic, Barcelona, Spain 23
University Hospital of Rangueil, Toulouse, France 10
University Hospital Halle (Saale), Halle, Germany 10
Ghent University Hospital, Ghent, Belgium 6
University Saarland, Homburg/Saar, Germany 4
University of Florence, Careggi Hospital Florence, Italy. 2
Total 120
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Kidney transplantation (KT) is considered the preferred
treatment for patients with end-stage renal disease (ESRD)
owing to the greater survival rate and better quality of life in
comparison to hemodialysis [1]. Although the open
approach remains the gold standard, minimally invasive
techniques have been introduced to decrease the morbidity
andmortality of open surgery [2], which could be especially
important in immunocompromised and fragile KT patients.
In 2002 Hoznek et al [3] described the possibility of
performing a robotic anastomosis in KT, and in 2010 the first
pure RAKT was performed by Giulianotti et al [4] in the
USAs. One of the major challenges in RAKT was to keep the
kidney cool during vascular anastomosis. Therefore, in
2014 Menon et al [5] standardized the technique with the
transperitoneal approach and regional hypothermia. The
authors highlighted that RAKT is a safe technique with
possible advantages such as low intra- and postoperative
complications, better cosmetic results, and superlative
vision that could result in better quality of the vascular
and ureteral anastomoses. In Europe, the first RAKT was
performed by Boggi et al [6] in 2011 as a hybrid case with
robotic vascular anastomosis and open ureterovesical
anastomosis. The first two European pure RAKTs were
performed in July 2015 by Doumerc et al [7] and Breda et al
[8]. A year later, Breda et al [9] reported surgical and
functional outcomes for 17 patients undergoing RAKT.
Starting from these preliminary pure RAKT results, a
European Robotic Urological Society (ERUS) RAKT group
was created with the aim of collecting prospective data on
RAKT in a common database.
The primary objective of this study was to evaluate
perioperative and early postoperative surgical outcomes for
RAKT performed in eight European institutions. Secondary
objectives included functional outcomes and correlations
between surgical data and functional results.
2. Patients and methods
2.1. Study design
This was a multicenter prospective observational study on RAKT
predominantly from living donors performed at eight European centers
(Table 1). The project was integrated in the ERUS RAKT working group to
collect prospective data on RAKT.
2.2. Study sample
Data for 120 nonconsecutive patients undergoing RAKT were prospec-
tively collected between July 2015 and May 2017 following institutional
review board approval and patient informed consent. Computed
tomography was performed for both recipients and donors to identify
renal vascular anomalies and iliac artery atherosclerosis. The inclusion
criteria were: patients with ESRD (considered as glomerular filtration
rate [GFR] <20 ml/min and/or symptomatic uremia and/or need for
dialysis); a matched living or deceased donor; >18 yr of age; and
body mass index (BMI) 40 kg/m2. The exclusion criteria were: iliac
artery atherosclerosis; malignancy; positive virology; severe comorbid-
ity (cardiovascular, pulmonary, or hepatic); highly complex vascularanatomy (ie, >3 arteries, >1 small accessory artery, >2 veins); multiple
previous abdominal surgeries; previous transplant (second transplant);
or simultaneous dual or multiple organ transplant.
2.3. Study variables and outcomes
Data for sociodemographic variables, surgical and functional outcomes,
and early postoperative complications with minimum follow-up of 1 mo
were prospectively collected.
The surgical outcomes evaluated included cold and warm ischemia
time and rewarming time. Warm ischemia time is the period between
renal circulatory arrest and the beginning of cold storage; cold ischemia
time is the duration of cold storage, with or without perfusion with a
storage solution, before introduction of the graft into the recipient.
Rewarming time is the time between removal of the kidney from cold
storage and the start of reperfusionwhile continuously adding ice slush.
Other surgical data analyzed were overall operative time, console time,
vascular anastomosis time, ureteral reimplantation time, and estimated
blood loss. Intraoperative complications included intraoperative vascu-
lar injuries, the need for vascular anastomosis revision, and conversion to
open surgery in the event of massive bleeding or low blood flow on
Doppler ultrasound evaluation. The early (30 d) postoperative compli-
cation rate was reported according to the Clavien-Dindo classification
[10].
The functional outcomes considered were serum creatinine and
estimated GFR (eGFR) on postoperative day (POD) 1, 3, 7, and 30. eGFR
was calculated using the Modified Diet in Renal Disease equation
(patient>18 yr old) [11,12]. Delayed graft function (DGF) was considered
as a need for dialysis in the first postoperative week. Among the
functional outcomes, we also included postoperative hemoglobin,
evaluation of postoperative pain using a visual analog score (VAS),
postoperative hospitalization, and time to double-J removal.
2.4. Surgical procedure (Si/Xi da Vinci)
The first standardization of RAKTwas described byMenon et al [5] in the
IDEAL phase 2a study. Following this technique, Breda et al [9] reported
their first RAKT results with details of the technical aspects and surgical
steps. The possible transvaginal introduction route has been described by
Doumerc et al [8]. The surgical procedure was standardized in all
participant centers. The main surgical steps are summarized and shown
in Figures 1–5.
2.5. Surgical experience
All surgical teams involved in this study have thorough expertise in the
field of robot-assisted surgery and open KT, with several hundred
procedures of each approach performed. Before starting on human
[(Fig._1)TD$FIG]
Fig. 1 – (A) A 6-cm linear incision along the umbilicus. (B) GelPOINT wound retractor placement in the linear periumbilical incision.
(C) Four-fingerbreadth access to the peritoneal cavity. (D) Introduction of the kidney wrapped in gauze filled with ice slush. (E) GelPOINT cap
(with camera trocar) placement. (F) Re-docking of the robot.
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technique on animal models, with proctoring by a more experienced
RAKT surgeon during training and when performing the first case(s) in
their own center following the standardized approachmentioned above.
2.6. Statistical analysis
Data for the demographic characteristics and comorbidities of recipients
and for donor characteristics were recorded in a common database.
Qualitative variables were described using absolute frequencies and
percentages. Quantitative variables were described using the mean,
standard deviation (SD), median, and quartiles. The Kolmogorov-
Smirnov test was used to assess the normality of distributions.
Linear relationships between surgical variables (operative and
ischemia times) and biomarkers (creatinine [mmol/l and eGFR
[ml/min/1.73 m2]) were analyzed using the Pearson test. Follow-up
changes in biomarkerswere also calculated and analyzed using aWilcoxon
test. Surgical variables were transformed as ordinal variables using
[(Fig._2)TD$FIG]
Fig. 2 – (A) Transvaginal GelPOINT placement. (B) Introduction of ttercile values andwere comparedwith biomarkers using aMann-Whitney
U test. For all tests, p < 0.05 was considered statistically significant. The
statistical package R-Studio (V 3.5) was used for statistical analyses.
3. Results
3.1. Descriptive characteristics
A total of 120 patients were recruited. Demographic data
and graft characteristics are summarized in Table 2.
3.2. Surgical data and functional results
Surgical data are reported in Table 3. The median estimated
blood loss was 150 ml, with median hemoglobin of
110 mg/dl preoperatively and 101, 95 and 98 mg/dl on
POD 1, 3, and 7, respectively. Two patients were converted tohe graft through the vaginal cavity into the abdominal cavity.
[(Fig._3)TD$FIG]
Fig. 3 – (A) A 2-cm incision of the GelPOINT cap with a scalpel. (B,C) Introduction of a modified Toomey tip syringe through the GelPOINT.
(D) Introduction of ice slush through the GelPOINT into the pelvis using the modified Toomey tip syringe.
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ultrasound evaluation immediately after skin closure and
they account for the longest operative times.
Preoperative functional data and postoperative func-
tional results in terms of creatinine and eGFR on POD 1, 3, 7,
and 30 are summarized in Table 4. A significant improve-
ment in renal function (serum creatinine and eGFR) was
observed progressively at all postoperative time points. We
[(Fig._4)TD$FIG]
Fig. 4 – Venous anastomosis. (A) External iliac vein incision using robotic sciss
continuous fashion to the external iliac vein using 6/0 Gore-Tex on a CV-6 need
checking the water tightness of the venous anastomosis by infusing heparinizcould not find a correlation between total operative time or
rewarming time and postoperative creatinine or eGFR
(Tables 5 and 6).
Themedian VAS pain scorewas 5, 4, 3, and 2 at 12, 24, 36,
and 48 h, after surgery. The median hospital stay was 7 d
(range 4–8 d). The median double-J dwell time was 28 d
(range 14–60). Five cases (4.2%) of DGF were reported. No
arterial or ureteral strictures occurred.ors. (B–D) The graft renal vein is anastomosed in an end-to-side
le (W.L. Gore and Associates Inc., Flagstaff, AZ, USA). (E) Venting and
ed saline solution using a 3F ureteral catheter or feeding tube.
[(Fig._5)TD$FIG]
Fig. 5 – Arterial anastomosis. (A) Laparoscopic vascular punch used to create a circular arterial hole. (B) Circular hole in the external iliac artery. (C,D)
Arterial anastomosis performed in an end-to-side continuous fashion using 6/0 Gore-Tex on a CV-6 needle (W.L. Gore and Associates Inc.). (E) Venting
and checking the water tightness of the arterial anastomosis. (F) Completed arterial anastomosis.













Median age at surgery, yr (interquartile range) 43.0 (19.0)
Median body mass index, kg/m2 (interquartile range) 25.2 (5.9)
Median dialysis duration, d (interquartile range) 365 (33–420)
Donor, live/cadaveric (n) 118:2




Urological anomalies, single/multiple ureter (n) 119/1
Graft introduction, transabdominal/transvaginal (n) 116/4
Table 3 – Surgical data
Median (IQR)
Operative time (min) 250.0 (80.0)
Console time (min) 160.0 (60.0)
Warm ischemia time (min) 2.0 (2.0)
Cold time ischemia (min) 34.0 (11.0)
Rewarming time (min) 50.0 (11.5)
Total ischemia time (min) 89.5 (21.5)
Arterial anastomosis time (min) 19.0 (6.5)
Venous anastomosis time (min) 20.0 (6.5)
Vascular anastomosis time (min) 38.0 (12.5)
Ureterovesical anastomosis time (min) 21.0 (7.0)
Estimated blood loss (cm3) 150 (113)
IQR = interquartile range.
Table 4 – Preoperative and postoperative functional data
Preoperative POD 1
Creatinine (mmol/l) 517.0 (230.4) 288.7 (201.5)
eGFR (ml/min/1.73 m2) 10.0 (6.0) 21.2 (14.6)
POD = postoperative day.
All comparisons (preoperative vs POD 7; POD 1 vs POD 7; preoperative vs POD 3
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Postoperative complications, recorded according to the
Clavien-Dindo classification, are summarized inTable 7. One
case (0.8%) of wound infection, three cases (2.5%) of ileus,
and four cases (3.3%) of bleeding (three of which requiredMedian (interquartile range)
POD 3 POD 7 POD 30
155.0 (101.2) 131.5 (63.0) 130.0 (59.3)
45.0 (32.3) 52.6 (24.2) 58.0 (27.8)
0; POD 1 vs POD 30) are statistically significant (p < 0.001).
Table 5 – Correlation between operating time and analytical
variables at POD 1, 7, and 30, and POD 7 – POD 1 and
POD 30 – POD 1 differences
Pearson correlation p value
POD 1
Creatinine (mmol/l) 0.114 0.237
eGFR (ml/min/1.73 m2) 0.123 0.208
POD 7
Creatinine (mmol/l) 0.001 0.993
eGFR (ml/min/1.73 m2) 0.096 0.322
POD 30
Creatinine (mmol/l) 0.074 0.446
eGFR (ml/min/1.73 m2) 0.101 0.297
Difference POD 1 – POD 7
Creatinine (mmol/l) 0.161 0.094
eGFR (ml/min/1.73 m2) 0.247 0.012
Difference POD 30 – POD 1
Creatinine (mmol/l) 0.183 0.059
eGFR (ml/min/1.73 m2) 0.190 0.054
POD = postoperative day; eGFR = estimated glomerular filtration rate.
Table 7 – Complications graded according to the Clavien-Dindo
classification for 120 robot-assisted kidney transplantation
procedures
Complications n (%)
Grade I 5 (4.2)
Wound infection 1 (0.8)
Bleeding (observation) 1 (0.8)
Ileus 3 (2.5)
Grade II 4 (3.3)
Deep venous thrombosis 1 (0.8)
Bleeding requiring blood transfusion 3 (2.5)
Grade IIIa 1 (0.8)
Lymphocele 1 (0.8)
Grade IIIb 8 (6.7)
Arterial thrombosis 3 (2.5)
Bleeding requiring surgical exploration 5 (4.2)
Grade IV 0 (0)
Grade V 0 (0)
Total 18 (15)
EU RO P E AN U RO LOGY 73 ( 2 018 ) 2 7 3 – 2 8 1278blood transfusion), managed conservatively, were observed.
One case (0.8%) of deep venous thrombosis required
anticoagulant drugs. One case (0.8%) of lymphocele
required percutaneous drainage. Three cases (2.5%) of
transplantectomy due to massive arterial thrombosis were
recorded. In five cases (4.2%), surgical exploration was
performed for intraperitoneal hematoma (on POD 2 in
2 cases, POD 3 in 2 cases, and POD 4 in 1 case). None of the
patients experienced more than one complication.
4. Discussion
Patients with ESRD are generally immunocompromised and
fragile. Accordingly, they may gain significant benefits from
KT performed using a minimally invasive approach.
Minimally invasive techniques in KT (laparoscopic and
robotic approaches) have recently been introduced to
increase perioperative and postoperative benefits such asTable 6 – Correlation between rewarming time and analytical variables a
Median
Re
48 min (n = 37) 48–
POD 1
Creatinine (mmol/l) 305.7 (232.6)
eGFR (ml/min/1.73 m2) 20.9 (16.6)
POD 7
Creatinine (mmol/l) 123.2 (56.4)
eGFR (ml/min/1.73 m2) 53.0 (36.1)
POD 30
Creatinine (mmol/l) 120.0 (46.3)
eGFR (ml/min/1.73 m2) 64.0 (26.0)
Difference POD 1 – POD 7
Creatinine (mmol/l) 140.8 (188.3) 
eGFR (ml/min/1.73 m2) 31.6 (27.1)
Difference POD 30 – POD 1
Creatinine (mmol/l) 136.9 (202.5) 
eGFR (ml/min/1.73 m2) 42.8 (30.1)
POD = postoperative day; eGFR = estimated glomerular filtration rate.shorter hospital stay, minimal postoperative pain, shorter
convalescence period, fewer wound infections, and better
cosmetic results, as observed for minimally invasive radical
prostatectomy [2].
Following the first European experience in RAKT [7,8],
the robotic approach in KT is now performed in a few
European centers as an alternative to the open approach in
selected patients. To date, 120 RAKTs, mainly from living
donors (98%), have been performed in this prospective
nonrandomized pilot study. Surgical aspects, functional
outcomes, and postoperative complication rates were
evaluated in this series, which, to the best of our knowledge,
is the largest reported on RAKT.
Regarding the surgical aspects, our multicenter prospec-
tive study confirms that RAKTcan be performed by surgeons
with extensive experience in robotic and transplant surgery,
even in the early stages of their learning curve. We would
like to stress that to obtain such results, the eight surgeonst POD 1, 7, and 30, and POD 7 – POD 1 and POD 30 – POD 1 differences
(interquartile range) p value
warming time
55 min (n = 33) 55 min (n = 41)
291.3 (145.0) 279.0 (201.1) 0.862
19.4 (8.4) 22.1 (15.2) 0.227
118.0 (63.8) 145.0 (62.4) 0.551
48.0 (26.1) 53.0 (23.0) 0.112
130.0 (42.0) 137.0 (60.0) 0.587
51.0 (28.0) 55.0 (30.4) 0.040
143.5 (82.7) 140.8 (153.2) 0.931
25.5 (25.4) 27.6 (26.8) 0.125
144.0 (92.4) 147.0 (201.2) 0.883
30.2 (24.4) 32.9 (18.5) 0.012
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humans. Furthermore, the surgeons were proctored during
their first four cases to reduce possible mistakes during
their learning curve.
In terms of functional outcomes, the most important
aspect to consider in KT performed from living donors is
patient and graft survival. In a recently published system-
atic review, no significant differences were observed
between the different approaches used (open, laparoscopic,
and robotic) in terms of patient and graft survival [13]. For
open KT the rate of DGF from living donors has been
reported to be up to 4% [14], while the reported prevalence
of arterial graft thrombosis is between 0.5% and 3.5% [15]. In
our multicenter study, we observed five cases (4.2%) of DGF
and three cases (2.5%) of arterial thrombosis with graft loss.
These results are in line with the literature on open KT,
although we note that they could also be related to a
learning curve process (with possible technicalmistakes) as
the lost grafts were at the beginning of the RAKT program.
However, the safety of the procedure and graft outcome
should be guaranteed even during the learning curve.
Therefore, proctoring and careful patient selection (eg,
suitable BMI and no previous abdominal surgery) are
important during the learning phase. It is important to
emphasize that a high level of expertise is required in KT
and robotic surgery [16]. Theoretically, particularly during
the learning curve, performing RAKTs fromdeceased donors
would possibly reduce the stress related to the surgery.
However, recipients of kidneys fromdeceased donors have a
high incidence of arterial atherosclerosis that can poten-
tially compromise arterial clamping and/or vascular anas-
tomosis during this phase. Another important aspect to
consider is that it is crucial for success that the surgery
always has to be performed by the same dedicated team.
This would be very difficult to achieve at times for deceased
donor transplantation (ie, night shifts, difficulty in using the
robot at night).
So far, it is not completely known whether the intra-
abdominal temperature during vascular anastomosis has a
potentially detrimental effect. When using the robotic
approach, maintaining a constant low temperature during
the rewarming time is a challenge. The impact of potentially
longer duration of rewarming during RAKTon graft function
remains unclear [17]. However, to avoid graft impairment
during the rewarming time, a regional hypothermia
technique for RAKT was described by Menon et al [5] in
their IDEAL phase 2a study. The authors reported use of a
gauze jacket filled with ice slush to wrap the kidney during
vascular anastomosis, with continuous addition of ice slush
for intraperitoneal cooling of the graft. The limitation of this
cooling device is the gradual intra-abdominalmelting of ice,
which might result in renal allograft impairment when
there is an extended vascular anastomosis time. Even
though it has been confirmed by other authors that this
technique is safe and effective [8,18], many concerns remain
regarding local and possibly systemic complications related
to the use of intraperitoneal cooling to maintain the graft at
a constant low temperature. Tugcu et al [19] reported
paralytic ileus as a complication of the use of ice slush, andno ileus occurred when the amount of ice slush was
decreased. The three cases of ileus (2.5%) that we observed
could also have been caused by intraperitoneal ice cooling.
The potential damage to the graft as a result of
pneumoperitoneum and the associated increase in intra-
abdominal pressure is not fully known. According to the
literature, both renal function and renal blood flow are
decreased during pneumoperitoneum, potentially leading
to graft impairment. The extent of these reductions depends
on preoperative renal function, hydration, and pneumoper-
itoneum pressure and duration [20].
In our series, we described a wide range of both overall
operative and ischemia times. This reflects the different
learning curves of the surgeons as well as the time loss for
open conversion in two cases and the presence of two
deceased donors in our series. Furthermore, we could not
find a correlation between operative time (including graft
exposure to pneumoperitoneum) or rewarming time and
graft function (Tables 5 and 6).
In general, the typical technical advantages of robotic
surgery are related to the use of articulated instruments, a
three-dimensional view, superb magnification (12), and
good surgeon ergonomics. Furthermore, correct use of the
da Vinci robotic system possibly provides benefits in terms
of patient outcomes, including a significant decrease in
blood loss, a low postoperative complication rate, and
shorter hospital stay [21]. Oberholzer et al [22] showed the
advantages of RAKT in an obese population; from a
technical point of view, as reported by Breda et al [7,9],
other advantages of RAKT are related to the quality of the
vascular anastomosis.
According to a recently published systematic review,
minimally invasive techniques in KT, including RAKT, have
shown promising results, particularly with regard to
complications and recovery [13]. In terms of complications,
our experience is in line with that in other RAKT series
reported [5]. Unlike open KT [23], lymphocele is an
uncommon complication in RAKT. The intraperitoneal
window left during RAKT allows natural drainage of lymph
into the peritoneal space. In addition, the wound infection
rate seems to be very low, with only one case (0.8%)
reported in a patient with diabetes and hypertension.
Sood et al [18] reported that RAKT is a safe surgical
alternative to open KT, reducing postoperative pain and
analgesic requirement with a better cosmetic result (Fig. 6).
We also observed a low postoperative VAS pain score that
rapidly decreased, with a mean hospital stay of 6 1 d.
Length of hospital stay may be considered another possible
advantage of RAKT compared to the mean stay for open
series (9  7 d) [24].
One of the limitations of the present study is possible
bias in the selection process. The eight centers included in
the study are high-volume centers. Despite this, a limited
number of recipientswere included in the study. This can be
explained not only by the inclusion and exclusion criteria
but also by the cost limitations of the procedure (some
centers had a limited number of procedures accepted per
year) and patient preference. Furthermore, not all centers
started to recruit patients at the same time. Another
[(Fig._6)TD$FIG]
Fig. 6 – Final esthetic result at 2 mo after robot-assisted kidney
transplantation.
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uniform manner. For this reason, no adequate conclusions
can be drawn regarding patients’ cosmetic satisfaction.
From the point of view of cosmetics and postoperative
recovery, the transvaginal graft introduction technique
described by Doumerc et al [8] and used in our series in four
cases (Fig. 2) may be considered an optimal alternative in
female recipients. A further limitation of our study is the
lack of a control group of patients who underwent open KT
from a living donor. A randomized controlled trial and
longer follow-upwould permit establishment of RAKT as an
alternative to open KT.5. Conclusions
To the best of our knowledge, this is the first and largest
reported multicenter prospective study on RAKT. In our
European patient group, RAKT has been proven to be an
advanced application for KT. Surgical data show that RAKT is
safe, feasible, and reproducible when performed by
surgeons with experience in both robotic and KT surgery.
Use of a robotic technique also has lowcomplication rates in
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